etoposide has been researched along with azacitidine in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (30.77) | 18.7374 |
| 1990's | 8 (15.38) | 18.2507 |
| 2000's | 12 (23.08) | 29.6817 |
| 2010's | 16 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bednarski, PJ; Flemming, A; Harms, M; Hein, M; Köckerling, M; Lalk, M; Langer, P; Libnow, S; Methling, K; Michalik, D; Reinke, H; Wende, K | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carter, SK; Slavik, M | 1 |
| Wiernik, PH | 1 |
| Lichtenfeld, KM; Van Echo, DA; Wiernik, PH | 1 |
| Brunner, KW; Cavalli, F | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Camitta, BP; Clavell, LA; Gelber, RD; Grier, HE; Link, MP; Weistein, HJ | 1 |
| Abella, E; Alvarado, CS; Chauvenet, A; Dubowy, R; Harris, M; Inoue, S; Krischer, JP; Ravindranath, Y; Ritchey, AK; Wiley, J | 1 |
| Buckley, JD; Hammond, GD; Lampkin, BC; Woods, WG | 1 |
| Gray, RG; Rees, JK | 1 |
| Camitta, B; Holbrook, T; Krischer, J; Land, VJ; Sexauer, C; Steuber, CP | 1 |
| Anderson, K; Coleman, M; Cuttner, J; Schiffer, CA | 1 |
| Lampkin, BC | 1 |
| Dahl, GV; Jackson, CW; Kalwinsky, DK; Look, AT; Mirro, J | 1 |
| Castleberry, R; Hakami, N; Harris, R; Krischer, J; Look, AT; Ravindranath, Y; Steuber, PC; Vietti, TJ | 1 |
| Catovsky, D; Chessells, JM; Galton, DA; Goldman, JM; Hann, IM; Hoffbrand, AV; Marcus, RE; Newland, AC; Prentice, HG; Stevens, RF | 1 |
| Gray, R; Hayhoe, FG; Rees, JK | 1 |
| Chan, HS; Estrov, Z; Freedman, MH; Weitzman, SS | 1 |
| Cabanillas, F | 1 |
| DeBellis, R; Kasdorf, H; Schiffer, CA; Wiernik, PH | 1 |
| Dahl, GV; Look, AT; Mauer, AM; Rivera, G | 1 |
| Bowman, WP; Dahl, GV; Evans, WE; Kalwinsky, D; Look, AT; Rivera, G | 1 |
| Gahrton, G | 1 |
| Camitta, B; Holbrook, T; Krischer, J; Land, V; Mahoney, D; Sexauer, C; Steuber, CP; Weinstein, H | 1 |
| Camitta, B; Carroll, AJ; Chang, M; Gresik, MV; Raimondi, SC; Ravindranath, Y; Steuber, CP; Weinstein, H | 1 |
| Cardoso, RS; Dias, FL; Guimarães, AP; Kronka, SN; Sakamoto-Hojo, ET | 1 |
| Adachi, M; Asano, T; Fujii, H; Fukunaga, Y; Hasegawa, K; Horichi, N; Isoe, T; Nakamura, K; Ohmori, T; Otake, N | 1 |
| Choi, HY; Jeon, YK; Kim, CW; Kim, H; Kim, JE; Kim, YA; Kim, YN; Park, SO; Park, SS | 1 |
| Ikeda, H; Imai, K; Itoh, F; Kobayashi, T; Mita, H; Sasaki, Y; Shinomura, Y; Suzuki, H; Tokino, T; Toyota, M | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Ammerpohl, O; Fölsch, UR; Kalthoff, H; Koch, D; Müerköster, SS; Schäfer, H; Sipos, B; Tsao, MS; Werbing, V | 1 |
| Karp, J | 1 |
| Bauer, K; Brillant, C; Engert, A; Herbst, C; Kluge, S; Monsef, I; Skoetz, N | 1 |
| Heo, DS; Jang, JY; Jeon, YK; Kim, CW; Kim, TM; Kim, WY; Paik, JH | 1 |
| Accardi, R; Creveaux, M; Guillermier, S; Herceg, Z; Shukla, R; Siouda, M; Sylla, BS; Tommasino, M; Yue, J | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Borchardt, C; Clemens, D; Dirksen, U; Frühwald, MC; Kool, M; Unland, R | 1 |
| Clozel, T; Elemento, O; Erdem, Z; Hassler, MR; Krzywinski, M; Robinson, BD; Shariat, SF; Xylinas, E; Zhuang, D | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D | 1 |
| Fukuda, M; Hosokawa, M; Iwakawa, S; Masuda, A; Tanaka, S; Ueda, K | 1 |
| Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A | 1 |
| Benner, A; Bernhard, H; Derigs, HG; Döhner, H; Döhner, K; Gaidzik, V; Ganser, A; Girschikofsky, M; Göhring, G; Grießhammer, M; Haase, D; Herr, W; Hertenstein, B; Heuser, M; Koller, E; Krauter, J; Kremers, S; Kuendgen, A; Lange, E; Martens, UM; Paschka, P; Ringhoffer, M; Salih, HR; Schlenk, RF; Teleanu, V; Thol, F; Wattad, M; Weber, D; Westermann, J; Wolf, D; Wulf, G | 1 |
4 review(s) available for etoposide and azacitidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Investigational drugs under study by the United States National Cancer Institute.
Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Chemical Phenomena; Chemistry; Chromomycins; Cisplatin; DNA, Neoplasm; Drug Evaluation, Preclinical; Etoposide; Humans; Ifosfamide; Leukemia L1210; Mice; Mitosis; National Institutes of Health (U.S.); Neoplasms; Neoplasms, Experimental; Razoxane; Tegafur; Teniposide; United States | 1976 |
Cell kinetics as related to treatment of patients with acute nonlymphoid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Cycle; Child; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Flow Cytometry; Hematopoietic Stem Cells; Humans; Hydrocortisone; Leukemia; Methotrexate; Mitotic Index; Neoplastic Stem Cells; Prednisone; Prognosis; Vincristine | 1985 |
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinones; Antibodies, Monoclonal; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Immunotherapy; Infant; Interferons; Leukemia; Leukemia, Lymphoid; Liposomes; Middle Aged; Mitoxantrone; Naphthacenes; Prognosis; Teniposide; Transplantation, Homologous; Transplantation, Isogeneic; Vinblastine; Vindesine | 1983 |
15 trial(s) available for etoposide and azacitidine
| Article | Year |
|---|---|
[New substances in oncologic therapy].
Topics: Altretamine; Ancitabine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Mitolactol; Nitrosourea Compounds; Razoxane; Remission, Spontaneous; Tamoxifen; Time Factors; Vinca Alkaloids; Zinostatin | 1978 |
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Prednisolone; Survival Analysis; Vincristine | 1992 |
Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Pilot Projects; Randomized Controlled Trials as Topic; Remission Induction; Thioguanine; Vincristine | 1990 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Drug Combinations; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Nimustine; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine; United Kingdom; Vincristine | 1990 |
Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Pilot Projects | 1991 |
Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia group B Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypotension; Infusions, Parenteral; Kidney Diseases; Leukemia, Myeloid; Male; Middle Aged | 1985 |
Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male | 1986 |
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Random Allocation; Remission Induction; Risk; Thioguanine; United Kingdom | 1987 |
The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; England; Etoposide; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission Induction; Thioguanine; Vincristine | 1987 |
[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoguazone; Recurrence | 1981 |
Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local | 1996 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Epigenesis, Genetic; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Treatment Outcome | 2017 |
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Etoposide; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Nucleophosmin; Prospective Studies; Young Adult | 2019 |
33 other study(ies) available for etoposide and azacitidine
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Synthesis of indirubin-N'-glycosides and their anti-proliferative activity against human cancer cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glycosides; Humans; Indoles; Models, Molecular; Molecular Conformation; Stereoisomerism; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
The therapy of acute leukemia in the adult: a progress report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Azacitidine; Blood Transfusion; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Patient Isolation; Platelet Transfusion; Pneumonia; Prednisone; Pyrimethamine; Remission, Spontaneous; Thioguanine; Vincristine; Zinostatin | 1976 |
Vinblastine, 5-azacytidine, and VP-16-213 therapy for previously treated patients with acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Azacitidine; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Vinblastine | 1977 |
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Azacitidine; Child; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisone; Remission Induction; Thioguanine; Vincristine | 1992 |
Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia; Male; Remission Induction; Time Factors | 1987 |
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Thioguanine | 1987 |
Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213.
Topics: Adult; Aged; Azacitidine; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Podophyllotoxin | 1982 |
Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Azacitidine; Cell Division; Child; Child, Preschool; DNA, Neoplasm; Drug Resistance; Etoposide; Female; Flow Cytometry; Humans; Infant; Kinetics; Leukemia; Male; Mitosis; Podophyllotoxin | 1982 |
Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood.
Topics: Acute Disease; Azacitidine; Child; Drug Therapy, Combination; Etoposide; Humans; Leukemia; Podophyllotoxin; Prednisone; Vincristine | 1982 |
Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study
Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Life Tables; Male; Multicenter Studies as Topic; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Risk Factors; Survival Analysis; Thioguanine; Translocation, Genetic; Treatment Failure; Treatment Outcome; United States | 2000 |
Chromosomal aberrations induced by 5-azacytidine combined with VP-16 (etoposide) in CHO-K1 and XRS-5 cell lines.
Topics: Animals; Azacitidine; Cell Cycle; Cell Line; CHO Cells; Chromosome Aberrations; Cricetinae; Cytogenetic Analysis; Drug Combinations; Drug Interactions; Etoposide; Kinetics; Mutagens; Radiation Tolerance | 2003 |
Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Blotting, Northern; Carubicin; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Humans; Immunoblotting; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Resistance to Fas-mediated apoptosis is restored by cycloheximide through the downregulation of cellular FLIPL in NK/T-cell lymphoma.
Topics: Antibodies, Monoclonal; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Proliferation; Cell Survival; Cycloheximide; Death-Associated Protein Kinases; Decitabine; Down-Regulation; Enzyme Activation; Etoposide; fas Receptor; Humans; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Killer Cells, Natural; Lymphoma, T-Cell, Peripheral; Protein Synthesis Inhibitors | 2005 |
The role of T-fimbrin in the response to DNA damage: silencing of T-fimbrin by small interfering RNA sensitizes human liver cancer cells to DNA-damaging agents.
Topics: Actins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Azacitidine; Carcinogens; Cell Cycle; Cell Line, Tumor; Cell Separation; Cytoskeleton; Decitabine; DNA Damage; DNA Methylation; Etoposide; Flow Cytometry; G2 Phase; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoblotting; Liver Neoplasms; Membrane Glycoproteins; Microfilament Proteins; Microscopy, Fluorescence; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Time Factors; Transfection; Ultraviolet Rays | 2005 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases.
Topics: Animals; Apoptosis; Azacitidine; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Nucleus; Coculture Techniques; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Etoposide; Female; Fibroblasts; Gemcitabine; Humans; Mice; Mice, SCID; Pancreatic Neoplasms; STAT1 Transcription Factor; Transfection | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Bleomycin; Chlorambucil; Controlled Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Exercise; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Vinblastine; Vincristine | 2010 |
MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Child; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Kaplan-Meier Estimate; Lymphoma, Extranodal NK-T-Cell; MicroRNAs; Middle Aged; NF-kappaB-Inducing Kinase; Prognosis; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Signal Transduction; TNF Receptor-Associated Factor 6; Treatment Outcome; Young Adult | 2011 |
Transcriptional regulation of the human tumor suppressor DOK1 by E2F1.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Azacitidine; Cell Line; Cell Line, Tumor; Cell Proliferation; Chromatin Assembly and Disassembly; Decitabine; DNA Damage; DNA Methylation; DNA-Binding Proteins; E2F1 Transcription Factor; Etoposide; Gene Silencing; HEK293 Cells; Humans; Methyltransferases; Phosphoproteins; Response Elements; RNA-Binding Proteins; Transcriptional Activation | 2012 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Doxorubicin; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Polycomb Repressive Complex 2; Rhabdoid Tumor; Vorinostat | 2015 |
An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Topics: Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Decitabine; Doxorubicin; Drug Resistance, Neoplasm; Epigenomics; Etoposide; Homeodomain Proteins; Humans; Hydroxamic Acids; Methylation; Neoadjuvant Therapy; Promoter Regions, Genetic; Urinary Bladder Neoplasms; Vinblastine; Vorinostat | 2016 |
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Camptothecin; Colonic Neoplasms; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Etoposide; Gemcitabine; HCT116 Cells; Humans; Irinotecan; Phosphorylation | 2017 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |